PATENT CLAIM ANALYSIS

Application Number: 15748548
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-08
Patent Classification: ["424", "449000"]

Abstract:
The present invention provides a transdermal delivery system comprising (R)-dihydroetorphine, or a salt, hydrate or derivative thereof, wherein said system has a rapid onset of (R)-dihydroetorphine plasma concentration characterised by the mean in vivo plasma concentration of (R)-dihydroetorphine achieving at least 50% of its C max  in less than 20 hours, preferably in less than 18 hours and more preferably in less than 12 hours, after application of the system to the skin of a human subject, e.g. when based on the mean plasma concentration versus time curve.

Claim (Index 24):
A system as claimed in  claim 1 , wherein the mean in vivo plasma concentration of (R)-dihydroetorphine is at least 50 pg/ml for at least 72 hours, after C max  is achieved and when a single patch having a size of 25 cm 2  and comprising 6.25 mg of (R)-dihydroetorphine is applied.

Metadata:
- Claim Count in Document: 96.0
- Percentile: 86.0
- Lexical Diversity: 1.65625
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14992122', '10736043', '11558663', '12181142', '10544259']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6602630676893632
- 35 USC 102 Novelty (BERT): 0.4933675583492574
- Combined Prediction Score: 0.6435735167553526
- Mean Citation Score: 174.41531
- Max Citation Score: 193.65048
- Similarity Product: 135.9112687794113

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test